The Effect of Aspirin as an Irreversible COX1 Inhibitor in Preventing Non-Valvular Atrial Fibrillation After Coronary Bypass Surgery
Background: We investigated whether the use of aspirin (irreversible COX1 inhibitor) in the preoperative period may prevent non-valvular atrial fibrillation, which is the most common rhythm problem in the postoperative period. Non-valvular atrial fibrillation after coronary surgery may lead to an increase in hospital costs due to excessive drug use and long-term hospitalization.
Methods: More than 1000 coronary artery bypass grafting operations were performed between January 2011 to and Nov 2018. The 572 patients were included in this study. Patients were divided into two groups as medication (n=292) and medication-free group (n=280). In the medication group, while patients received aspirin (300 mg daily) therapy (up to 5 days) before the operation, the other group did not receive any anti-aggregan treatment. The patients were followed up for the occurrence of atrial fibrillation from the early postoperative period up to 3 months.
Results: While non-valvular atrial fibrillation was developed in 16 patients (5,5 %) in medication group, this rate was 24,3 % with 68 patients in medication-free group 3 month after operation (P < .05). In addition to the intensive care unit and hospital stay, there was a significant difference between the groups in terms of hospital costs (P < .05).
Conclusions: According to the results of our study, we found that the aspirin used in preoperative period may prevent non-valvular atrial fibrillation in the postoperative period. In relation to these results; we found that hospital stay and hospital expenses decreased.
Balcetyte-Harris N, Tamis JE, Homel P, et al. 2002. Randomized study of early intravenous esmolol versus oral beta-blockers in preventing post-CABG atrial fibrillation in high risk patients identified by signal-averaged ECG: Results of a pilot study. Ann Noninvasive Electrocardiol 7: 86–91.
Chaney MA. 2002. Corticosteroids and cardiopulmonary bypass: a review of clinical investigations. Chest 121:921—31.
Camm AJ, Kirchhof P, Lip GY, et al. 2010. European Heart Rhythm Association; European Association for Cardio- Thoracic Surgery. Guidelines for the management of atrial fibril- lation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31: 2369 –429.
Fuster V, Ryden LE, Cannom DS, et al. 2006. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257–e354.
Gaudino M, Andreotti F, Zamparelli R, et al. 2003. The 174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation 108: 195—9.
Goettea A, Lendeckel U. 2004. Nonchannel drug targets in atrial fibrillation. Pharmacol Ther 102: 17—36.
Ho KM, Tan JA. 2009. Benefits and risks of corticosteroid prophylaxis in adult cardiac surgery: a dose-response meta-analysis. Circulation 119: 1853–66.
Imazio M, Brucato A, Ferrazzi P, et al. 2011. Colchicine Reduces Postoperative Atrial Fibrillation: Results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) Atrial Fibrillation Substudy Circulation 124: 2290-95.
Khan MF, Wendel CS, Movahed MR. 2013. Prevention of Post–Coronary Artery Bypass Grafting (CABG) Atrial Fibrillation: Efficacy of Prophylactic Beta-Blockers in the Modern Era. A meta-analysis of latest randomized controlled trials. Ann Noninvasive Electrocardiol 18: 58–68.
Kim YH, Lim DS, Lee JH, et al. 2003. Gene expression profiling of oxidative stress on atrial fibrillation in humans. Exp Mol Med 35: 336 – 49.
Lin PH, Lee SH, Su CP, Wei YH. 2003. Oxidative damage to mitochon- drial DNA in atrial muscle of patients with atrial fibrillation. Free Radic Biol Med 35: 1310 – 8.
Maisel WH, Rawn J, Stevenson WG. 2001. Atrial fibrillation after cardiac surgery. Ann Intern Med 135: 1061–73.
Maniar PB, Balcetyte-Harris N, Tamis JE, et al. 2003. Intravenous versus oral beta-blockers for prevention of post-CABG atrial fibrillation in high-risk patients identified by signalaveraged ECG: Lessons of a pilot study. Card Electrophysiol Rev 7: 158–61.
Mihm MJ, Yu F, Carnes CA, et al. 2001. Impaired myofibrillar energetics and oxi- dative injury during human atrial fibrillation. Circulation 104: 174 –80.
Neuman RB, Bloom HL, Shukrullah I, et al. 2007. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem 53: 1652—7.
Ozaydin M, Peker O, Erdogan D, et al. 2008. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. European Heart Journal 29: 625–31.
Paparella D, Yau TM, Young E. 2002. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update. Eur J Cardiothorac Surg 21:232—44.
Patti G, Chello M, Candura D, et al. 2006. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After cardiac surgery) study. Circulation 114: 1455–61.
Paull DL, Tidwell SL, Guyton SW, et al. 1997. Beta blockade to prevent atrial dysrhythmias following coronary bypass surgery. Am J Surg 173: 419–21.
Ramlawi R, Out H, Mieno S, et al. 2007. Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. Ann Thorac Surg 84: 1166—73.
Reinhart K, Baker WL, Ley-Wah Siv M. 2011. Beyond the guidelines: new and novel agents for the prevention of atrial fibrillation after cardiothoracic surgery. J Cardiovasc Pharmacol Ther 16: 5–13.
Tomic V, Russwurm S, Moller E, et al. 2005. Transcriptomic and proteomic patterns of systemic inflammation in on-pump and off-pump coronary artery bypass grafting. Circulation 112: 2912–20.
Wijeysundera DN, Beattie WS, Djaiani G, et al. 2005. Off-pump coronary artery surgery for reducing mortality and morbidity: Meta-analysis of randomized and observational studies. J Am Coll Cardiol 46: 872–82.
Villareal RP, Hariharan R, Liu BC, et al. 2004. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 43:742–8.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).